MARINUS PHARMACEUTICALS INC

NASDAQ: MRNS (Marinus Pharmaceuticals, Inc.)

Last update: 5 days ago, 11:12PM

0.328

0.03 (8.25%)

Previous Close 0.303
Open 0.301
Volume 2,262,622
Avg. Volume (3M) 2,295,367
Market Cap 18,062,044
Price / Sales 3.14
Price / Book 3.17
52 Weeks Range
0.260 (-20%) — 11.26 (3333%)
Earnings Date 5 Nov 2024 - 11 Nov 2024
Operating Margin (TTM) -375.94%
Diluted EPS (TTM) -2.66
Quarterly Revenue Growth (YOY) 32.50%
Current Ratio (MRQ) 2.28
Operating Cash Flow (TTM) -120.47 M
Levered Free Cash Flow (TTM) -66.13 M
Return on Assets (TTM) -57.75%
Return on Equity (TTM) -2,986.55%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Marinus Pharmaceuticals, Inc. Bearish -

Stockmoo Score

0.4
Analyst Consensus 1.0
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 2.5
Technical Oscillators -2.5
Average 0.38

Similar Stocks

Stock Market Cap DY P/E P/B
MRNS 18 M - - 3.17
JAZZ 7 B - 18.72 1.84
ARWR 2 B - - 7.54
SPRY 1 B - - 6.86
VIR 1 B - - 1.02
PHAT 1 B - - -

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 0.96%
% Held by Institutions 78.71%

Ownership

Name Date Shares Held
Sofinnova Investments, Inc. 30 Jun 2024 4,151,576
Suvretta Capital Management, Llc 30 Jun 2024 3,820,012
Abrdn Plc 30 Sep 2024 2,658,527
Ikarian Capital, Llc 30 Jun 2024 706,154
52 Weeks Range
0.260 (-20%) — 11.26 (3333%)
Price Target Range
0.500 (52%) — 11.00 (3254%)
High 11.00 (HC Wainwright & Co., 3,254.68%) Buy
Median 4.00 (1,119.88%)
Low 0.500 (Jefferies, 52.49%) Hold
Average 5.07 (1,446.20%)
Total 5 Buy, 2 Hold
Avg. Price @ Call 0.839
Firm Date Target Price Call Price @ Call
Cantor Fitzgerald 25 Oct 2024 4.00 (1,119.88%) Buy 0.405
24 Sep 2024 13.00 (3,864.62%) Buy 1.90
Jefferies 25 Oct 2024 0.500 (52.49%) Hold 0.405
RBC Capital 25 Oct 2024 1.00 (204.97%) Hold 0.405
EF Hutton 24 Oct 2024 3.00 (814.91%) Buy 0.296
17 Oct 2024 23.00 (6,914.33%) Buy 1.74
JMP Securities 23 Sep 2024 10.00 (2,949.71%) Buy 1.63
Oppenheimer 23 Sep 2024 6.00 (1,729.83%) Buy 1.63
HC Wainwright & Co. 14 Aug 2024 11.00 (3,254.68%) Buy 1.10

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria